Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia Clinical Trial

Official title:

Phase 2 Study of Decitabine and Cedazuridine in Combination With Venetoclax for AML Relapse After Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05799079
• Other study ID #: VICCHEM2163
• Status: Recruiting
• Phase: Phase 2
• Start date: January 29, 2024
• Est. completion date: March 2029

Study information

• Verified date: May 2024
• Source: Vanderbilt-Ingram Cancer Center
• Contact: Vanderbilt-Ingram Services for Timely Access
• Phone: 800-811-8480
• Email: cip[@]vumc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial tests how well decitabine and cedazuridine (DEC-C) works in combination with venetoclax in treating acute myeloid leukemia (AML) in patients whose AML has come back after a period of improvement (relapse) after a donor stem cell transplant. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving DEC-C in combination with venetoclax may kill more cancer cells in patients with relapsed AML.

Description:

PRIMARY OBJECTIVE:

I. To assess the effect of DEC-C/venetoclax on the investigator-assessed composite complete remission (CR) rate (CR/complete remission with partial hematologic recovery [CRh]/complete remission with incomplete hematologic recovery [CRi]).

SECONDARY OBJECTIVES:

I. To assess the rate of partial response (PR) and morphologic leukemia free state (MLFS) following treatment with DEC-C/venetoclax. II. To assess the relapse free survival of patients treated with DEC-C/venetoclax.

III. To assess overall survival of patients treated with DEC-C/venetoclax. IV. To assess the safety and tolerability of DEC-C/venetoclax in the post-hematopoietic cell transplant (HCT) setting.

V. To assess the rates of measurable residual disease negativity in patients achieving a CR.

OUTLINE:

Patients receive venetoclax orally (PO) daily for 28 days in a 28-day cycle. Patients receive DEC-C PO daily on days 1-5 of a 28-day cycle. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 51
• Est. completion date: March 2029
• Est. primary completion date: March 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF and meet all study requirements

• History of morphologically confirmed AML (per World Health Organization [WHO] diagnostic criteria) with evidence of disease recurrence (>= 5% blasts consistent with prior disease) that occurs after allogeneic hematopoietic cell transplantation (HCT). Patients transplanted for another indication (e.g., myelodysplastic syndrome/chronic myelomonocytic leukemia [MDS/CMML]) who relapse with AML are eligible to enroll

• White blood cells (WBC) must be less than 25,000/ul for at least three days prior to cycle 1, day 1 (C1D1) (hydroxyurea allowed)

• A bone marrow biopsy must be performed and tissue collected for entrance to the trial

• Eastern Cooperative Oncology Group Performance Status of 0 - 2

• Alanine transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) and/or aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) less than or equal to 3x upper limit of normal (ULN)

• Total bilirubin < 1.5 x ULN

• Patients with Gilbert's syndrome (hereditary indirect hyperbilirubinemia) must have a total bilirubin of < 3 x ULN

• Calculated creatinine clearance >= 30 ml/min (per the Cockroft-Gault formula)

• Willingness to abide by all study requirements, including contraception, maintenance of a pill diary, and acceptance of recommended supportive care medications

Exclusion Criteria:

• Prior relapse or progression while receiving venetoclax or other commercially available or investigational BCL-2 inhibitor

• Anticancer therapy, including investigational agents =< 2 weeks or =< 5 half-lives of the drug, whichever is shorter, prior to C1D1. (Use of hydroxyurea is permitted)

• Inadequate recovery from toxicity attributed to prior anti-cancer therapy to =< Grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version [v]5.0), excluding alopecia or fatigue

• History of allogeneic HCT, or other cellular therapy product, within 3 months of signing consent

• Clinically active acute or chronic graft versus host disease (GVHD). Patients must be off calcineurin inhibitors for at least 4 weeks to be eligible

• Radiation therapy or major surgery within 3 weeks of signing consent

• Active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible. Prophylaxis is acceptable

• Inability to tolerate oral medication, presence of poorly controlled gastrointestinal disease, or dysfunction that could affect study drug absorption

• Active documented central nervous system leukemia

• Concurrent treatment with a non-permitted concomitant medication

• Other malignancy IF currently being treated or likely to be treated in next 6 months except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ

• Pregnancy or breastfeeding females

• Known chronic alcohol or drug abuse

• Clinically significant cardiovascular disease with major event or cardiac intervention within the past 6 months (e.g. percutaneous intervention, coronary artery bypass graft, documented cardiac heart failure) as determined by the investigator

• Any other condition deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Recurrent Acute Myeloid Leukemia

Intervention

Drug:
• Venetoclax
Given by mouth
• Decitabine
Given by mouth
• Cedazuridine
Given by mouth

Procedure:
• Bone Marrow Aspiration and Biopsy
Undergo bone marrow biopsy
• Biospecimen Collection
Undergo blood sample collection

Locations

Country	Name	City	State
United States	Vanderbilt University/Ingram Cancer Center	Nashville	Tennessee

Sponsors (3)

Lead Sponsor	Collaborator
Sanjay Mohan	National Comprehensive Cancer Network, Taiho Oncology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite complete response (CR) rate (CR/complete response with partial recovery of peripheral blood counts [CRh]/complete remission with incomplete hematological recovery [CRi])	Categorical variables (e.g., objective response) will be summarized in frequency tables and compared among patient subgroups using the chi-square test. Linear regression and logistic (or ordinal logistic) regression will be used to construct multivariable models for continuous, binary, and ordinal variables, as appropriate. In addition to ORR, the distributions of progression-free and overall survival will be estimated using the Kaplan-Meier method. We will consider statistical comparisons statistically, but not necessarily clinically, significant for p<0.05.	Up to 24 months post-treatment.
Secondary	Rate of partial response (PR) following treatment with DEC-C/venetoclax		Up to 24 months post-treatment.
Secondary	Rate of morphologic leukemia free state (MLFS) following treatment with DEC-C/venetoclax		Up to 24 months post-treatment.
Secondary	Rate of relapse free survival		Up to 24 months post-treatment.
Secondary	Rate of overall survival	The distributions of progression-free and overall survival will be estimated using the Kaplan-Meier method.	Up to 24 months post-treatment.
Secondary	Incidence of adverse events		Up to 24 months post-treatment.
Secondary	Rate of measurable residual disease negativity in patients achieving a CR		Up to 24 months post-treatment.